InflaRx NV
IFRX1.110USD
+0.050+4.72%
收盤 12/19, 16:00（美東）報價延遲15分鐘
75.20M總市值
虧損本益比TTM
關於 InflaRx NV 公司
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV簡介
公司代碼IFRX
公司名稱InflaRx NV
上市日期Nov 08, 2017
CEORiedemann (Niels C)
員工數量74
證券類型Ordinary Share
年結日Nov 08
公司地址Winzerlaer Str. 2
城市JENA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編07745
電話493641508180
網址https://www.inflarx.de/
公司代碼IFRX
上市日期Nov 08, 2017
CEORiedemann (Niels C)
InflaRx NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
收入明細
單位: USD更新時間: 3月5日 週三
單位: USD更新時間: 3月5日 週三
FY2022
FY2021
FY2020
FY2019
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Germany
0.00
0.00%
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
其他
77.94%
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
其他
77.94%
股東類型
持股股東
佔比
Hedge Fund
17.39%
Individual Investor
6.38%
Research Firm
5.02%
Venture Capital
2.91%
Investment Advisor
1.12%
Investment Advisor/Hedge Fund
1.06%
Bank and Trust
0.02%
其他
66.11%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
77
16.63M
24.55%
-5.58M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Jun 30, 2025
683 Capital Management LLC
2.48M
3.65%
-150.00K
-5.71%
Jun 30, 2025
RA Capital Management, LP
1.97M
2.91%
+1.97M
--
Jun 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.64M
2.42%
-35.55K
-2.12%
Jun 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Ikarian Capital LLC
705.01K
1.04%
+705.01K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
693.35K
1.02%
-567.80K
-45.02%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
InflaRx NV的前五大股東是誰？
InflaRx NV的前五大股東如下：
Suvretta Capital Management, LLC持有股份：6.48M佔總股份比例：9.57%。
683 Capital Management LLC持有股份：2.48M佔總股份比例：3.65%。
RA Capital Management, LP持有股份：1.97M佔總股份比例：2.91%。
Guo (Renfeng M.D.)持有股份：1.76M佔總股份比例：2.60%。
Eversept Partners, LP持有股份：1.64M佔總股份比例：2.42%。
Suvretta Capital Management, LLC持有股份：6.48M佔總股份比例：9.57%。
683 Capital Management LLC持有股份：2.48M佔總股份比例：3.65%。
RA Capital Management, LP持有股份：1.97M佔總股份比例：2.91%。
Guo (Renfeng M.D.)持有股份：1.76M佔總股份比例：2.60%。
Eversept Partners, LP持有股份：1.64M佔總股份比例：2.42%。
InflaRx NV的前三大股東類型是什麼？
InflaRx NV 的前三大股東類型分別是：
Suvretta Capital Management, LLC
BofA Global Research (US)
683 Capital Management LLC
Suvretta Capital Management, LLC
BofA Global Research (US)
683 Capital Management LLC
有多少機構持有InflaRx NV(IFRX)的股份？
截至2025Q3，共有77家機構持有InflaRx NV的股份，合計持有的股份價值約為16.63M，占公司總股份的24.55% 。與2025Q2相比，機構持股有所增加，增幅為-12.91%。
哪個業務部門對InflaRx NV的收入貢獻最大？
在FY2022，--業務部門對InflaRx NV的收入貢獻最大，創收--，占總收入的--% 。
